Announcement • May 13
Whitehawk Therapeutics, Inc. announced that it expects to receive $87.499998 million in funding from a group of investors
Whitehawk Therapeutics, Inc. announced that it has entered into a securities purchase agreement with certain qualified institutional buyers and accredited investors to issue 4,330,866 common shares at an issue price of $3.92 for gross proceeds of $16,976,994.72 and 17,991,021 pre-funded warrants to acquire common stock at an issue price of $3.9199 for gross proceeds of $70,523,003.2179 for aggregate proceeds of $87,499,997.9379 before deducting placement agent fees and other private placement expenses on May 12, 2026. Certain executive officers, affiliated funds of directors, and a director of the company entered into the purchase agreement in connection with the PIPE financing, and committed to purchase an aggregate of $39,750,000 of shares of common stock and/or pre-funded warrants. The transaction includes participation from new investors, Coastlands Capital Partners LP, a fund managed by Coastlands Capital LP, QVT Family Office Fund LP, a fund managed by QVT Financial LP, Avoro Life Sciences Fund LLC, a fund managed by Avoro Capital Advisors LLC, StemPoint Capital Master Fund LP a fund managed by StemPoint Capital LP, Caley M. Castelein IRA, David J. Lennon, Scott Giacobello, Bryan Ball, ADAR1 Partners, LP, a fund managed by ADAR1 Capital Management, LLC, Spearhead Insurance Solutions Idf, Llc - Series Adar1, a fund managed by Spearhead Administrative Services, LLC, Margaret Dugna and from returning investors, Avicenna Life Sci Master Fund Lp, a fund managed by Invus Financial Advisors, LLC, Invus Public Equities, L.P., a fund managed by The Invus Group, LLC, Acuta Capital Fund, LP, Acuta Opportunity Fund, LP, a fund managed by Acuta Capital Partners, LLC, KVP Capital, LP, a fund managed by Kvp Capital Advisors, LP, Averill Master Fund, Ltd., a fund managed by Suvretta Capital Management, LLC, Averill Madison Master Fund, Ltd., a fund managed by Suvretta Capital Management, LLC. The pre-funded warrants will have an exercise price of $0.0001 per share of common stock, be immediately exercisable, and remain exercisable until exercised in full.
